Non-Alcoholic Steatohepatitis Drug Development Pipeline: An Update.

Non-alcoholic steatohepatitis (NASH) is a burgeoning global health crisis that mirrors the obesity pandemic. This global health crisis has stimulated active research to develop novel NASH pharmacotherapies targeting dysregulated inflammatory, cellular stress and fibrogenetic processes that include: 1) metabolic pathways to improve insulin sensitivity, de-novo lipogenesis, and mitochondrial utilization of fatty acids, 2) cellular injury or inflammatory targets that reduce inflammatory cell recruitment and signalling, 3) liver-gut axis targets that influence bile acid enterohepatic circulation and signalling, and 4) anti-fibrotic targets. In this review, we summarize several of the therapeutic agents that have been studied in phase 2 and 3 randomized trials. In addition to reviewing novel therapeutic drugs targeting nuclear receptor pathways, liver chemokine receptors, liver lipid metabolism, lipotoxicity or cell death, and glucagon-like peptide-1 receptors, we also discuss the rationale behind the use of combination therapy and the lessons learned from unsuccessful or negative clinical trials.